Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

NCT01093794 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Co-administration of 50 mg sitagliptin and 500 mg metformin
DRUG: sitagliptin/metformin 50 mg/500 mg tablet
DRUG: Co-administration of 50 mg sitagliptin and 850 mg metformin
DRUG: sitagliptin/metformin 50 mg/850 mg tablet

Sponsor

Merck Sharp & Dohme LLC